AL-611
Phase 1Small molecule
AL-611 is one of 49 small molecule programs targeting Hepatitis C Virus Infection. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
76 competitors in Hepatitis C Virus Infection
#DrugCompanyPhaseTrials
1Virazole
CConrado Roberto Hoffmann Filho
Approved
Cellcept
RocheApproved
Daklinza
Bristol-Myers SquibbApproved
Sovaldi
GileadPhase 3
Rayos
RRoxane Laboratories
Approved
Alinia
RRomark Laboratories L.C.
Approved
Promacta
GSKPhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Olysio
WWim Janssens
Phase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AL-611. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAlios Biopharma Inc.